E Fund Management Co. Ltd. Invests $476,000 in Arrowhead Pharmaceuticals, Inc. $ARWR

E Fund Management Co. Ltd. bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,841 shares of the biotechnology company’s stock, valued at approximately $476,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in shares of Arrowhead Pharmaceuticals by 30.2% during the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after acquiring an additional 10,496 shares during the period. AQR Capital Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the first quarter worth approximately $514,000. Goldman Sachs Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after purchasing an additional 447,456 shares during the last quarter. Empowered Funds LLC lifted its holdings in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 979 shares during the last quarter. Finally, Focus Partners Wealth boosted its stake in Arrowhead Pharmaceuticals by 1,339.5% in the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 15,123 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 2.2%

Shares of Arrowhead Pharmaceuticals stock opened at $87.47 on Friday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $19.82 and a 12-month high of $95.49. The company has a market capitalization of $12.32 billion, a price-to-earnings ratio of -38.88 and a beta of 1.27. The firm’s 50-day moving average price is $82.59 and its two-hundred day moving average price is $72.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same quarter in the previous year, the firm posted ($1.26) earnings per share. Arrowhead Pharmaceuticals’s quarterly revenue was up 171.0% compared to the same quarter last year. On average, analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on ARWR. Piper Sandler reaffirmed an “overweight” rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Leerink Partners lifted their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Chardan Capital boosted their target price on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. HC Wainwright upped their price target on shares of Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $97.33.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the transaction, the director owned 111,459 shares in the company, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director directly owned 31,600 shares of the company’s stock, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.